In vitro activity of the arylomycin natural product antibiotics against Staphylococcus epidermidis and other coagulase-negative staphylococci
P.A. Smith, M.E. Powers, T.C. Roberts, F.E. Romesberg, Antimicrob. Agents Chemother. (2011) 55:1130-1134.
We report the activity of a synthetic arylomycin derivative against clinical isolates of coagulase-negative staphylococci (CoNS). Against many important CoNS, e.g. S. epidermidis, S. haemolyticus, S. lugdunensis, and S. hominis, we find that the arylomycin has activity equal to or greater than that of vancomycin, the antibiotic most commonly used to treat CoNS infections.